Joint Pain Medicine in India: Classes & Guidelines

This joint pain medicine India overview covers where each drug class sits in current guidelines, why India has specifically restricted one commonly used NSAID, and how comorbidity changes which option a prescriber actually reaches for.

Why does OARSI recommend topical NSAIDs more strongly than oral ones?

Topical NSAIDs carry OARSI's strongest evidence grade, Level 1A, for knee osteoarthritis pain, reflecting a favourable risk-benefit profile from localised drug delivery rather than systemic exposure. Oral NSAIDs, by contrast, receive only a conditional recommendation for patients without significant comorbidity.

This gap widens further for patients with existing conditions. OARSI's guideline specifically does not recommend any oral NSAID for patients with cardiovascular comorbidity or frailty, and for patients with gastrointestinal risk factors, it favours COX-2 selective inhibitors or NSAID-plus-proton-pump-inhibitor combinations over a plain oral NSAID alone.

What restriction does India specifically place on nimesulide?

Nimesulide, a widely used NSAID in India, has been restricted in two stages. In 2011, the government banned nimesulide formulations for children under 12 years, following evidence that immature paediatric metabolic pathways raised the risk of severe hepatotoxicity from the drug.

A second, broader restriction followed in April 2025: the Drug Technical Advisory Board accepted an ICMR-recommended ban on 100mg oral nimesulide in immediate-release form specifically, based on the availability of safer alternative NSAIDs. Strengths below 100mg, and sustained- or extended-release formulations above 100mg, are not covered by this specific restriction.

Does paracetamol still have a role in joint pain management given these NSAID cautions?

Paracetamol remains widely used for joint pain, particularly where NSAID use is limited by cardiovascular, renal or gastrointestinal comorbidity, though current evidence generally places its analgesic effect below that of NSAIDs for osteoarthritis pain specifically. It carries a more favourable safety profile for the comorbidities that rule out oral NSAID use.

This makes paracetamol a common first step, or an adjunct, precisely in the patient population OARSI's guideline steers away from oral NSAIDs, rather than a universally preferred first-line agent ahead of NSAIDs across all patients.

When does joint pain management move beyond oral and topical medicine to an injection?

Intra-articular corticosteroid or hyaluronic acid injection becomes a guideline-supported option when oral and topical therapy fail to adequately control pain, or when a patient's comorbidity profile substantially limits oral NSAID use. This is a distinct treatment tier from the medicines discussed above, not a simple escalation of the same drug class.

The choice between corticosteroid and hyaluronic acid, and how it interacts with a patient's other medications, involves its own separate set of guideline considerations, which our companion piece on osteoarthritis injection interactions covers in detail.

Why does comorbidity matter more for joint pain drug choice than for many other conditions?

Joint pain is disproportionately common in older patients who are also more likely to carry cardiovascular disease, chronic kidney disease, or gastrointestinal risk factors, the exact comorbidities that most restrict oral NSAID use under current guidelines. This overlap means the "default" joint pain medicine for a young, comorbidity-free patient is frequently not appropriate for the population most affected by joint pain in practice.

Guideline-based prescribing for joint pain is therefore less about picking the most effective single drug in isolation and more about matching the safest effective option to a specific patient's comorbidity profile, a judgement that changes the actual prescription far more than the underlying diagnosis does.

What does this mean for a hospital pharmacy's joint pain medicine stocking?

A hospital dispensing joint pain medicine India patients rely on needs the full spread described here in stock at once: topical NSAIDs, multiple oral NSAID options, paracetamol, and injection-grade corticosteroid and hyaluronic acid products.

Comorbidity-driven prescribing means the exact mix a given patient needs is genuinely unpredictable in advance, which makes a narrow, low-diversity joint pain stock a frequent source of walked-out prescriptions.

Medyzen's managed hospital pharmacy services piece covers how a managed model is built to carry this kind of comorbidity-driven product breadth reliably, and the prescription leakage piece covers what repeated stock gaps cost a hospital across a patient population this large. Our osteoarthritis injection drug interactions piece covers the injection tier in more clinical depth.

Sources

1. 1OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis — Osteoarthritis and Cartilage, Osteoarthritis Research Society International, 2019
2. 2Pharmaceutical treatment of osteoarthritis — Osteoarthritis and Cartilage
3. 3Nimesulide's rise and reckoning in India: ending with a nationwide ban on high-dose use — reporting on the Drug Technical Advisory Board decision and ICMR recommendation
4. 4Global ban on nimesulide — International Research Journal of Modernization in Engineering, Technology and Science
5. 5Recommendations for the management of hip and knee osteoarthritis: a systematic review of clinical practice guidelines — Osteoarthritis and Cartilage

This article is for informational purposes and is not a substitute for professional medical advice. It describes drug classes and guideline positioning, not dosing or individual prescribing decisions. Consult a treating physician for individual case management.